EGFR and nasopharyngeal carcinoma: A total of 206 patients with LA-NPC were included in this study, including 121 (58.7%) patients with IC alone, 57 (27.7%) patients with IC combined with anti-PD-1, and 28 (13.6%) patients with IC combined with anti-EGFR.